Schizophrenia – HCP
Schizophrenia – HCP supports educational providers delivering independent healthcare professional education on antipsychotics and long-acting injectables to improve treatment competence and prevent relapse.
Funder: Teva
Due Dates: At least 60 days before the required decision date | At least 60 days before activity start (complete request)
Funding Amounts: Support for independent medical education
Summary: Supports healthcare professional education on schizophrenia treatment, antipsychotics, and long-acting injectables to improve competence, recognize non-adherence, and prevent relapse.
Key Information: Grants are awarded to educational providers, not individuals, including individual healthcare professionals.
Description
Teva’s Schizophrenia – HCP grant supports independent education that improves understanding of schizophrenia and its burden on patients and caregivers. Its objectives include increasing competence in treatment, recognizing non-adherence, preventing relapse, and understanding suboptimal efficacy and subsequent treatment considerations. Teva seeks evidence-based, clinically relevant, performance-based education.
Educational priorities include the mechanisms of action, receptor-binding profiles, and clinical data of current and emerging antipsychotics. The program also addresses barriers to using long-acting injectables (LAIs), clinical considerations when switching treatments, and the importance of broadening LAI use as reflected in literature and recent guidelines. Intended learners include psychiatrists, nurse practitioners, physician assistants, nurses, pharmacists, medical trainees, medical students, interns, residents, fellows in community and inpatient settings, and managed care healthcare professionals.
